![BeardBros_BlogImages [Recovered]](data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMjU2MCAyOTIiIHdpZHRoPSIyNTYwIiBoZWlnaHQ9IjI5MiIgeG1sbnM9Imh0dHA6Ly93d3cudzMub3JnLzIwMDAvc3ZnIj48L3N2Zz4=)
Key Takeaways
- Washington debates two paths for federal marijuana legalization: rescheduling to Schedule III or descheduling altogether.
- Descheduling offers a chance to address past injustices, such as wrongful convictions, while Schedule III may limit access to large corporations.
- The Cannabis Administration and Opportunity Act aims to remove cannabis from federal scheduling but proposed taxes could burden the industry further.
- While Schedule III offers some benefits, it does not equate to true legalization nor does it free those still incarcerated for cannabis-related offenses.
- The industry must advocate for comprehensive reform that includes descheduling and justice for those affected by prohibition.
Washington is once again presenting the country with two very different versions of cannabis reform. One would move marijuana from Schedule I to Schedule III of the Controlled Substances Act. The other would remove cannabis from federal scheduling altogether, establish a national regulatory structure, address past convictions and begin repairing some of the damage caused by prohibition. These are not minor variations of the same policy. Rescheduling asks how the federal government should continue controlling cannabis, while descheduling asks why cannabis should remain federally controlled and criminalized at all.
That matters as Senate Democrats reintroduce the Cannabis Administration and Opportunity Act while the Trump administration continues pursuing the far narrower Schedule III approach. The Senate proposal is far from perfect, particularly when it comes to the heavy federal taxation it could impose on an industry already drowning under state taxes, local fees, compliance costs and years of punishment under Internal Revenue Code Section 280E. Even with those flaws, descheduling is still unquestionably preferable to Schedule III because one path begins dismantling prohibition, while the other risks rebuilding it around corporations, pharmaceutical companies and investors with enough money to survive federal regulation.
The government’s central hypocrisy remains impossible to ignore. Federal officials are now preparing to recognize that cannabis has accepted medical value, yet people remain incarcerated under laws built on the claim that it did not. Washington appears increasingly comfortable discussing cannabis research, federal tax relief, pharmaceutical development and corporate investment. It remains far less comfortable discussing the people whose freedom was taken under the same policies now being reconsidered.
The Government Cannot Call Cannabis Medicine and Keep Its Prisoners
For decades, the federal government placed marijuana in Schedule I, a category supposedly reserved for substances with no accepted medical use and a high potential for abuse. That classification supported arrests, prosecutions, mandatory minimum sentences, property seizures and the destruction of families and communities. Patients were criminalized, cultivators were portrayed as dangerous traffickers and defendants were sentenced under laws that treated cannabis as one of the most threatening substances in the country.
If marijuana moves to Schedule III, the federal government will have officially abandoned one of the central claims used to justify prohibition. However, the people sentenced under that system will not automatically receive relief. Their convictions will remain, their sentences will continue and their families will keep waiting. The government may admit that cannabis has medical value without accepting responsibility for the punishments imposed while it insisted otherwise.
That is not a technical oversight. It is a political choice. Washington has found urgency when cannabis reform could benefit companies, investors, pharmaceutical developers and tax collectors. It has not shown the same urgency when reform could return people to their families or clear the records that continue blocking access to housing, employment and education. The government is preparing to change the legal status of cannabis while refusing to fully confront what its old position did to human beings.
What the Federal Legalization Bill Would Change
The Cannabis Administration and Opportunity Act would remove cannabis from the Controlled Substances Act instead of simply shifting it to another schedule. It would preserve state authority, establish federal rules for taxation, public health and interstate commerce, and create a framework for regulating cannabis as a legal industry rather than a prohibited drug market.
The bill also includes provisions addressing certain federal cannabis convictions, sentencing relief, banking access, federal benefits, small-business support and reinvestment in communities harmed by prohibition. Those justice provisions are not side issues. They are what separate a market reform bill from an attempt to correct an injustice.
The modern cannabis industry did not suddenly appear when lawmakers discovered tax revenue. It was built by patients, growers, caregivers, advocates and underground operators who carried the plant through the most dangerous years of prohibition. Many of those people never received licenses, investment opportunities or government assistance. They received criminal records, asset forfeiture and prison sentences.
Any legitimate federal legalization plan must address those people. Otherwise, legalization becomes little more than a transfer of wealth and control from the communities that built cannabis culture to the corporations now positioned to dominate it. The CAOA is imperfect, but it at least recognizes that federal reform must look backward as well as forward.
The Bill’s Taxation Is Excessive
Supporting descheduling does not require pretending that the Cannabis Administration and Opportunity Act gets everything right. Its proposed federal taxation is excessive, especially for an industry already burdened by state excise taxes, local taxes, licensing fees, testing costs, compliance expenses and years of federal tax punishment under Section 280E.
Many licensed cannabis businesses are barely surviving. Independent brands are disappearing, retailers are closing and cultivators are often forced to sell below production cost. In some states, excessive taxation has strengthened the illicit market by making licensed products too expensive while compliant businesses collapse under the weight of regulation.
Congress has repeatedly treated cannabis as an unlimited source of tax revenue rather than an emerging industry still recovering from prohibition. That approach is shortsighted and dangerous. A heavy federal tax layered on top of existing state and local taxes could accelerate consolidation and make it even harder for small and legacy businesses to compete.
The tax structure in the descheduling bill should be reduced, phased in slowly and designed around the financial reality of the current market. Small operators, social equity businesses and companies still recovering from years of 280E should not be forced to carry another oversized tax burden the moment federal prohibition ends.
Even so, excessive taxation is a problem that can be negotiated, amended or reduced. Schedule III creates a more fundamental problem because it keeps cannabis inside the Controlled Substances Act and risks placing the future of the industry in the hands of companies wealthy enough to navigate federal pharmaceutical regulation.
Schedule III Is Not Legalization
Moving marijuana to Schedule III would create real benefits. It would recognize accepted medical use, likely provide relief from Section 280E and potentially make scientific research easier. Those changes matter, particularly for licensed cannabis businesses that have been punished for years by a federal tax policy designed to target illegal drug trafficking.
Ending 280E could save jobs and keep struggling companies alive. It could give independent operators room to breathe and allow compliant businesses to deduct ordinary expenses like payroll, rent and marketing. Those benefits should not be dismissed.
However, Schedule III would not legalize cannabis. State adult-use markets would remain federally illegal. Interstate commerce would not automatically open. Federal cannabis convictions would not disappear, and people serving cannabis sentences would not automatically receive resentencing, clemency or release.
Marijuana would remain a federally controlled substance. Schedule III would change cannabis’s position within prohibition, but it would not end prohibition. The federal government should not be allowed to present a classification change as legalization, especially when so many of the criminal and commercial consequences of federal prohibition would remain intact.
Schedule III Could Hand Cannabis to Corporate America
The greatest long-term danger of Schedule III is not simply that it falls short of legalization. It is that it could reshape the cannabis industry around a federal system that only large corporations can afford to enter.
Schedule III substances usually exist within tightly controlled systems involving DEA registration, FDA oversight, approved manufacturing, clinical research, prescription requirements and complex federal compliance. State cannabis markets were not built that way. They include independent cultivators, small manufacturers, dispensaries, delivery companies, legacy brands and thousands of products that do not fit neatly into a pharmaceutical model.
Large corporations have the money to hire regulatory attorneys, lobbyists, clinical researchers and federal compliance teams. Small operators do not. Legacy businesses certainly do not. If federal agencies begin applying pharmaceutical-style requirements to cannabis, the companies most likely to survive will be those with the deepest pockets.
That could include major pharmaceutical firms, tobacco companies, alcohol conglomerates and heavily capitalized multistate operators. Schedule III might provide short-term tax relief while laying the groundwork for long-term corporate capture. The industry could escape 280E only to discover that legal participation now requires millions of dollars in legal, scientific and regulatory expenses.
That is not true reform. It is a new barrier to entry.
Descheduling Is Still the Better Path
Descheduling and rescheduling are fundamentally different. Rescheduling moves cannabis from one category of the Controlled Substances Act to another. Descheduling removes it from that system and creates the opportunity to regulate cannabis on its own terms.
The difference affects criminal enforcement, state markets, interstate commerce, federal benefits, immigration, employment, banking and criminal records. Schedule III accepts continued federal control and leaves the basic structure of prohibition in place. Descheduling begins replacing that structure with a cannabis-specific regulatory system.
The Senate legalization bill’s tax provisions need serious revision. The industry should oppose excessive taxation and any federal rules that disadvantage small, independent and legacy operators. Those problems, however, do not make Schedule III the better option.
Taxes can be changed. Regulations can be amended. A descheduled market gives lawmakers, states, advocates and businesses room to build something better. Schedule III keeps cannabis trapped inside a federal drug-control system never designed to support a diverse legal marketplace.
The real choice is not between a perfect legalization bill and Schedule III. No perfect bill exists. The choice is between an imperfect path out of prohibition and a more polished version of federal control.
Cannabis Prisoners Cannot Be Left Behind
The most offensive part of the Schedule III debate is that the government could officially recognize cannabis as medicine while continuing to imprison people for cannabis. Companies may receive tax relief, pharmaceutical firms may begin developing new products and federal agencies may build new regulatory structures, but none of that gives a prisoner back a year of freedom.
If the federal government changes marijuana’s classification because its previous position was medically and scientifically wrong, it must review the punishments imposed under that position. Congress can authorize resentencing. Courts can review sentences. The president can grant clemency. Federal agencies can identify people still incarcerated for conduct that would be viewed differently today.
The legal tools already exist. What is missing is political courage.
Federal cannabis reform that helps balance sheets while ignoring prison sentences is not justice. It is market reform for the powerful. A government willing to reconsider cannabis for the sake of research, taxation and corporate development should be equally willing to reconsider the human consequences of the laws it enforced.
The Industry Must Demand More Than Tax Relief
The cannabis industry has every reason to support relief from 280E. That tax policy has driven compliant companies toward insolvency and rewarded only those businesses with enough capital to absorb years of losses. Tax relief could preserve jobs, protect independent brands and stabilize struggling state markets.
However, the industry cannot declare victory once its federal tax bill improves. Cannabis reform was never supposed to end with better deductions for companies while people remained behind bars. It was supposed to end criminalization, clear records, repair communities and create a legal market that did not repeat the failures of prohibition.
Trade associations, investors and cannabis companies should demand descheduling, reasonable taxation, automatic expungement, resentencing, clemency and meaningful access for legacy operators. Anything less allows the legal industry to benefit from reform while abandoning the people who made reform possible.
The industry loses its moral authority when it becomes loud about taxation and quiet about incarceration. It cannot celebrate Schedule III as a complete victory while federal cannabis prisoners remain locked away and small operators face the prospect of being pushed out by pharmaceutical-style regulations.
Washington Must Choose
The federal government wants to recognize cannabis as medicine while preserving the laws used to punish people for it. It wants cannabis tax revenue without fully addressing the damage caused by prohibition. It wants legal commerce, but only on terms that may favor the companies best equipped to satisfy federal regulators.
That position is becoming impossible to defend.
The Cannabis Administration and Opportunity Act needs work. Its taxation is too aggressive, and its regulatory structure must protect small, independent and legacy businesses. Even with those flaws, descheduling remains the better path because it creates an opening to end federal prohibition rather than simply modernize it.
Schedule III may help research and relieve 280E, but it also threatens to leave cannabis inside a system built for corporate pharmaceuticals. It could make legal participation easier for companies with armies of attorneys while doing almost nothing for prisoners, legacy operators or communities harmed by enforcement.
Federal cannabis reform should be measured by more than tax savings and stock prices. It should be measured by how many records are cleared, how many sentences are reviewed, how many people come home and how many independent businesses are allowed to survive.
Anything less preserves the ugliest contradiction of prohibition: cannabis becomes legitimate when powerful institutions are ready to profit from it, while the people punished for carrying the plant this far remain locked away.
That is not legalization. It is prohibition under new management.
Frequently Asked Questions
No. Schedule III would keep marijuana within the Controlled Substances Act. It could recognize medical use and provide tax relief, but state adult-use markets would remain federally illegal.
No. Rescheduling would not automatically release prisoners, reduce sentences or clear criminal records. Separate clemency, expungement or resentencing measures would be required.
Descheduling removes cannabis from the Controlled Substances Act and creates a path toward legalization, state protections and criminal justice reform. Schedule III maintains federal control and could favor large corporations capable of navigating pharmaceutical regulation.
The bill’s proposed federal taxes are excessive for an industry already burdened by state taxes, local fees and years of Section 280E. Those provisions should be reduced, but the bill’s descheduling approach remains preferable to Schedule III.
Yes. Large corporations are better positioned to afford federal registration, research, legal counsel and regulatory compliance. Small and legacy cannabis businesses could be pushed out if cannabis is forced into a pharmaceutical-style system.
Descheduling would remove cannabis from the federal controlled substances schedules. Additional regulations would still be required, but it would create the foundation for ending federal marijuana prohibition rather than merely modifying it.
